Newsfeeds Archive - Page 13 of 194

1 minute read

News

Sutro Biopharma Earlier Announced Luvelta Demonstrated Encouraging Preliminary Anti-Tumor Activity (29% Response Rate) In Late-stage Patients With Recurrent/relapsed Endometrial Cancer With Tumor Proportion Score (TPS) >25% Folrα Expression

October 22, 11:17 AM

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced initial results from a Phase 1

STRO

1 minute read

News

Janssen Earlier Announced TAR-200 Intravesical Delivery System Results Show 77% Complete Response Rate In Patients with Bacillus-Calmette-Guérin Unresponsive, High-Risk Non-Muscle-Invasive Bladder Cancer

By Charles Gross

October 22, 11:14 AM

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that data from the Phase 2b SunRISe-1 study evaluating the efficacy and safety of TAR-200 monotherapy in patients with Bacillus

JNJ

1 minute read

News

Olema Oncology Earlier Announced Phase 2 Monotherapy Clinical Study Results For Palazestrant; Showed Results Support Continued Development Of Palazestrant In The OPERA-01 Monotherapy Phase 3 Pivotal Trial

By Charles Gross

October 22, 11:11 AM

Olema Pharmaceuticals, Inc. ((&ldquo, Olema&rdquo, , &ldquo, Olema Oncology&rdquo, , or the &ldquo, Company&rdquo, , NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and

OLMA

1 minute read

News

Revolution Medicines Announced RMC-6236 Demonstrated Evidence Of Clinical Activity And Acceptable Safety Profile That Was Tolerated Across Dose Levels Analyzed

By Charles Gross

October 22, 11:06 AM

Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced promising anti-tumor and safety data for RMC-6236, its

RVMD

1 minute read

News

Exelixis Earlier Announced Cabozantinib Compared With Placebo Reduced Risk Of Disease Progression Or Death In Patients With Pancreatic NET And In Patients With Extra-Pancreatic NET

By Charles Gross

October 22, 10:56 AM

Exelixis, Inc. (NASDAQ:EXEL) today announced detailed results from CABINET, a phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) compared with placebo in two cohorts of patients with previously treated

EXEL

1 minute read

News

Seagen And Astellas Announced Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival In Patients Treated with PADCEV And KEYTRUDA In First-Line Advanced Bladder Cancer

By Charles Gross

October 22, 10:48 AM

Seagen Inc. (NASDAQ:SGEN) and Astellas Pharma Inc. (TSE:4503 “Astellas”) today announced results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) for PADCEV® (enfortumab vedotin-ejfv) in

ALPMY

1 minute read

News

Amgen Announced New Lumakras Plus Vectibix Data In Patients With KRAS G12c-mutated Metastatic Colorectal Cancer

By Charles Gross

October 22, 10:44 AM

Amgen (NASDAQ:AMGN) today announced data from the global Phase 3 CodeBreaK 300 trial evaluating two doses of LUMAKRAS® (sotorasib) (960 mg or 240 mg) in combination with Vectibix® (panitumumab). Both

AMGN

1 minute read

News

Merck Announced KEYTRUDA Plus Padcev Reduced Risk of Death By More Than Half Versus Chemotherapy In Patients With Previously Untreated Locally Advanced Or Metastatic Urothelial Cancer

By Charles Gross

October 22, 10:41 AM

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-A39 trial (also known as EV-302), which was conducted in collaboration with Seagen and Astellas,

MRK

2 minute read

News

Genmab And Seagen Announced TIVDAK Significantly Prolonged Overall Survival In Patients with Recurrent Or Metastatic Cervical Cancer Compared With Chemotherapy In Global Phase 3 innovaTV 301 Trial

By Charles Gross

October 22, 10:39 AM

Genmab A/S (Nasdaq: GMAB) and Seagen Inc.

GMAB

1 minute read

News

Janssen Announced Phase 3 MAGNITUDE Study Shows Trend Toward Improvement In Overall Survival in Patients With Metastatic Castration Resistant Prostate Cancer With BRCA Alterations Treated With Niraparib And Abirateron + Prednisone

By Charles Gross

October 22, 10:36 AM

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the final analysis (FA) of the Phase 3 MAGNITUDE study, in which a pre-planned multivariate analysis [MVA] showed niraparib, a

JNJ